28
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T9041 | AES-350 | Apoptosis , HDAC | |
AES-350 is a potent and orally active HDAC6 inhibitor(IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively). It is also against HDAC-3, -8, and -11 in an enzymatic activity assay with IC50 values of 0.187 μM, 0.245 μM, ... | |||
T9573 | GSK3685032 | DNA Methyltransferase | |
GSK3685032 is a non-covalent and selective DNMT1 inhibitor(IC50 = 36 nM). The inhibitory effect is time-independent and reversible. GSK3685032 induces loss of DNA methylation and transcriptional activation and inhibits c... | |||
T60002 | DC-S239 | Histone Methyltransferase | |
DC-S239 (DC-S239) is a selective inhibitor of histone methyltransferase SETD7 (IC50 = 4.59 μM) with anticancer activity. | |||
T3278 | Piribedil | EU-4200,Trivastan,ET-495,Trivastal | Dopamine Receptor , Histone Methyltransferase , Adrenergic Receptor |
Piribedil (Trivastan) is a dopamine D2 agonist, used in the treatment of Parkinson's disease. | |||
T62702 | Senexin C | CDK | |
Senexin C is a novel orally active and specific CDK8/19 inhibitor with potential anticancer activity.Senexin C is more metabolically stable and potent than Senexin B. Senexin C inhibits the growth of MV4-11 leukaemia cel... | |||
T27011 | CHMFL-FLT3-122 | CHMFLFLT3122,CHMFL FLT3 122 | FLT |
CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia. CHMFL-FLT3-122 significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft m... | |||
T77339 | BRD4-IN-4 | Epigenetic Reader Domain | |
BRD4-IN-4 is a selective BRD4 inhibitor with an IC50 value of 6.83 μM for BRD4.BRD4-IN-4 selectively inhibits the proliferation of the MV4-11 cell line and arrests the cells in G1 phase.BRD4-IN-4 can be used to study MLL... | |||
T72048 | CDK8-IN-12 | GSK-3 , CDK | |
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showe... | |||
T6138 | TCS 359 | FLT3 Inhibitor | FLT |
TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM. | |||
T2051 | SKLB4771 | FLT3-IN-1,FLT3-IN-1 | FLT |
SKLB4771 (FLT3-IN-1) is a novel potent and selective Flt3 inhibitor. | |||
T78818 | HDAC-IN-63 | ||
HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1. It effectively suppresses MV4-11 cell proliferation with an IC50 of 92 nM, induces apoptosis, and arrest... | |||
T24045 | ESM156 | eSM 156,eSM-156 | |
eSM156 is an effective FLT3 inhibitor. It has high antiproliferative activity against acute myeloid leukemia (AML) cells. eSM156 has IC50 (FLT3) = 1.4 nM; EC50 (MV4-11cells) = 150 nM; EC50 (MOLM-13 cells) = 40 nM. | |||
T60942 | MC2652 | ||
MC2652 (compound 1a) is a potent LSD1 inhibitor that shows high inhibitory effects in leukaemia cells MV4-11 and NB4. MC2652 has antiproliferative activity against LNCaP cells of prostate cancer [1]. | |||
T61768 | FY-56 | ||
FY-56, a highly potent and selective inhibitor of LSD1/KDM1A with an IC50 value of 42 nM, demonstrates significant selectivity over MAO-A/B. This compound effectively induces differentiation in MOLM-13 and MV4-11 cells, ... | |||
T61299 | PAK4-IN-2 | ||
PAK4-IN-2 is an exceptionally effective inhibitor of PAK4, exhibiting an IC 50 value of 2.7 nM. This compound is capable of arresting MV4-11 cells at the G0/G1 phase and inducing cell apoptosis. It holds significant pote... | |||
T62412 | FLT3-IN-12 | ||
FLT3-IN-12 is a selective, potent, orally active FLT3 kinase inhibitor that acts on FLT3-WT (IC50: 1.48 nM) and FLT3-D835Y (IC50: 2.87 nM). FLT3-IN-12 is more selective than c-KIT (>1000-fold). FLT3-IN-12 showed signific... | |||
T79420 | FLT3-IN-22 | ||
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant. This compound displays significant antiproliferative effects against MV4-11 ... | |||
T62260 | FLT3-IN-11 | ||
FLT3-IN-11 (compound 30) is an orally active, potent and selective inhibitor of FLT3 kinase, acting on wild-type FLT3 (IC50: 7.22 nM) and FLT3-D835Y (IC50: 4.95 nM). FLT3-IN-11 exhibited significant anti-AML effects with... | |||
T79683 | HDAC/CD13-IN-1 | Others | |
HDAC/CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound ef... | |||
T63490 | CDK9-IN-19 | ||
CDK9-IN-19 is a selective and potent CDK9 inhibitor (IC50: 2.0 nM). CDK9-IN-19 exhibits good anti-proliferative activity in cancer cells, moderate pharmacokinetic properties and low hERG inhibition. CDK9-IN-19 significan... | |||
T36681 | Sorafenib N-oxide | ||
Sorafenib N-oxide is an active metabolite of sorafenib , an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases. Sorafenib N-oxide inhibits FLT3 that contains the internal tandem duplication mutation (FLT3-ITD; Kd =... | |||
T4261 | BPR1J-097 hydrochloride (1327167-19-0(free base)) | FLT | |
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo. | |||
T79596 | FLT3-IN-20 | ||
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD. It exhibits anti-proliferative effects on FLT3-ITD-positive AML cell lines, with IC50s of 7 nM... | |||
T78871 | PLM-101 | ||
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, con... | |||
T62112 | CDK8-IN-6 | ||
CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers. | |||
T62354 | CDK8-IN-7 | ||
CDK8-IN-7 (compound 12) is a potent and selective inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 3.5 nM). CDK8-IN-7 has shown potential for AML-cancer research. | |||
T36628 | PROTAC BRD4 Degrader-8 | PROTAC BRD4 Degrader-8 | |
PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells... | |||
T39937 | M-808 | ||
M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM. |